Access to second-line ART regimens in LMIC is problematic, mainly because of the expense of HIV protease inhibitors (PI) [9], and CD4 monitoring is often the sole surrogate marker available to guide the management of the infection [10]. The gene discussed is CD4; the disease is infection.